PT  - JOURNAL ARTICLE
AU  - Betensky, Rebecca A.
AU  - Feng, Yang
TI  - Accounting for incomplete testing in the estimation of epidemic parameters
AID  - 10.1101/2020.04.08.20058313
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.08.20058313
4099  - http://medrxiv.org/content/early/2020/04/11/2020.04.08.20058313.short
4100  - http://medrxiv.org/content/early/2020/04/11/2020.04.08.20058313.full
AB  - As the COVID-19 pandemic spreads across the world and the United States, it is important to understand its evolution in real time and at regional levels. The field of infectious diseases epidemiology has highly advanced modeling and estimation strategies that yield relevant estimates. These include the doubling time of the epidemic, i.e., the number of days until the number of cases doubles, and various representations of the number of cases over time, including the epidemic curve and associated cumulative incidence curve. While these quantities are immediately estimable given current data, they suffer from dependence on the underlying testing strategies within communities. Specifically, they are inextricably tied to the likelihood that an infected individual is tested and identified as a case. We clarify the functional relationship between testing and the epidemic parameters of interest, and thereby derive sensitivity analyses that explore the range of possible truths under various testing dynamics. We demonstrate that crude estimates that assume stable testing or complete testing can be overly-optimistic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available at covidtracking.com https://covidtracking.com/data